Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.

102 A further retrospective study comparing TMZ alone (150 mg/m 2 for 5 days every 28 days) with RT alone in 86 elderly patients with newly diagnosed malignant glioma reported a higher median survival among those treated with TMZ alone, but the difference did not reach statistical significance (6.0 versus 4.1 months). 103 Dosage, administration, and formulation TMZ is used for the treatment of newly diagnosed as well as recurrent GBM and AA.

also in 111,027 other papers

This 1.5-month increase in mOS for TMZ-treated patients failed to reach statistical significance. 26 A further trial examining the role of TMZ in rAA enrolled 162 patients and reported a mOS of 13.6 months. 54 Data derived from the trial conducted by Wong and colleagues of patients receiving a variety of chemotherapeutic agents reported a mOS of 11 months among rAA patients. 55 Despite the failure of TMZ to improve survival outcome, these trials nevertheless demonstrated improvements in the novel endpoint PFS6m as well as HRQoL, leading to the approval of TMZ for the treatment of rGBM and rAA patients.

also in 6,035 other papers